GlockerEGrimbacherB.Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr Opin Allergy Clin Immunol. 2010;10:542-550.
2.
KirkpatrickCH.Chronic mucocutaneous candidiasis. Pediatr Infec Dis J. 2001;20197-206.
3.
FreemanAFHollandSM.Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res. 2009;65:32R-37R.
4.
AhonenPMyllarniemiSSipilaIPerheentupaJ.Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829-1836.
5.
GlockerEOHennigsANabaviMet al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727-1735.
PuelAPicardCCypowyjSLilicDAbelLCasanovaJL.Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?Curr Opin Immunol. 2010;22:467-474.
8.
van de VeerdonkFLPlantingaTSHoischenAet al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365:54-61.
9.
LiuLOkadaSKongXFet al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208:1635-1648.
10.
SmeekensSPPlantingaTSvan de VeerdonkFLet al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS ONE. 2011;6:e29248.
11.
van de VeerdonkF LNeteaMG.Treatment options for chronic mucocutaneous candidiasis. J Infect. 2016;72(suppl):S56-S60.
12.
MössnerRDieringNBaderOet al. Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infect Dis. 2016;62:951-953.
